通心络联合胰激肽原酶治疗糖尿病合并急性冠脉综合征的临床研究

Clinical study on treatment of diabete complicated with acute coronary syndrome with Tongxinluo and pancreatic kininogenase

目的观察通心络联合胰激肽原酶对糖尿病合并急性冠脉综合征患者的临床疗效。方法确诊为糖尿病合并急性冠脉综合征患者58例,分为治疗组(中西药联合)30例,对照组(单纯西药)28例,2组在控制血糖的基础上均给予胰激肽原酶治疗,治疗组在胰激肽原酶治疗的同时联合通心络。治疗3个月后观察疗效、活动度、生活质量、心肌标志物及不良反应情况。结果治疗组临床疗效与对照组比较差异无统计学意义(P>0.05),活动度及生活质量改善率均优于对照组(P<0.05)。治疗组治疗后心肌损伤标志物(cTnT、cTnI、CK-MB)的水平均显著下降,且优于对照组(P<0.05)。治疗组出血、消化道不良反应低于对照组(P<0.05),而肝肾损伤差异无统计学意义(P>0.05)。结论通心络联合胰激肽原酶可改善糖尿病合并急性冠脉综合征的疗效,提高活动度及生活质量,且不良反应轻微。

Objective To observe the therapeutic effect of Tongxinluo and pancreatic kininogenase on diabetic complicated with acute coronary syndrome（ACS）.Methods Fifty-eight patients with confirmed diagnosis of diabete complicated with acute coronary syndrome were randomly assigned to the treatment group（30 cases） and control group（28 cases）.Both groups were treated with pancreatic kininogenase,the traditional Chinese medicine Tongxinluo was given to the treatment group additionally.The therapeutic effect was observed and compared after 3 months therapy.Results Compared with the control group,the improvements in the treatment was belter in terms of majority of clinical symptoms karnofski score（P〈0.05）,also increasing behavior extent delay patients condition go step further develop（P〈0.05）,in decreasing levels of myocardium injure marks（serum cTnT,cTnI,CK-MB,P〈0.05）.In treatment group,the incidences of hemorrhage,gastrointestinal adverse reactions were lower than those of in control group（P〈0.05）,while no statistical difference in liver and kidney damage（P〈0.05）.Conclusion It demonstrated that the combination with the Tongxinluo and pancreatic kininogenase could improve the therapeutic effect of diabetic complicated with ACS.